We pre-treated ten different AML cell lines with IC50 doses of Bortezomib, Carfilzomib, or a DMSO control for a duration of 24 h and incubated them for 24 h with 100 ng/ml of FasL, 100 ng/ml of TRAIL or a PBS control after PI removal (Figure S10A). This evidence concerns the gene FASLG and acute myeloid leukemia.